New antibody shot could mean fewer HIV treatments

NCT ID NCT03254277

Completed Disease control Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a lab-made antibody called 3BNC117-LS in 43 people, some with HIV and some without. The goal was to see if it is safe and how long it stays in the body. If it works, this antibody might one day help control HIV with less frequent dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 3BNC117-LS (a lab-made antibody)
What this could lead to: If successful, this could lead to a longer-lasting antibody treatment that helps control HIV without daily pills.
What could go wrong: This is a very early Phase 1 safety study with only 43 participants. The antibody may not work as hoped, and side effects are possible. Much more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

The Rockefeller University

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.